The verified answer
As of Aug 2026, DEPLOY verifies Microbot Medical: 1 model, 1 active incident. 1 source back the record.
CategorySurgical robots
Overview
Microbot Medical Inc. (Nasdaq: MBOT) is a commercial-stage medical device company developing the LIBERTY Endovascular Robotic System, the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. The company received FDA 510(k) clearance in September 2025 and commenced limited market release in November 2025, expanding to a full market release in Q2 2026. Headquartered in Hingham, Massachusetts with R&D operations in Yokneam, Israel.
Verified record
- Verified deployments
- None on file
- Active incidents
- 1 incident on file
Key facts
FDA cleared
FDA clearance
Key feature
Tickersee public companies →
Category
Data & sources
Press releases
1
1 source backing this record.View all →
Models (1)
View all models →Microbot Medical on the deployment map
View the global mapMicrobot Medical has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.
No verified deployments for Microbot Medical on the DEPLOY record yet. Track Microbot Medical to know the moment the first one is verified.
Current leadership (3)
- Harel Gadot Chairman, President & CEOsecondary-verified
- Simon Sharon GM, Chief Technology Officersecondary-verified
- Rachel Vaknin Chief Financial Officersecondary-verified
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Microbot Medical (1)
- Microbot Medical receives FDA 510(k) clearance for Liberty endovascular robotic system2025-09-08 · Regulatory action
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Recent coverage
Microbot Medical in third-party press
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
Financial state
- Reporting basis
- private_reported
- Lifecycle stage
- growth
- Counterparty risk class
- low
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Funding rounds (2)
- Other2025-09-15
$92M(reported)
- IPO2016-01-01
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJul 2, 2026
Added to the verified registry
- Deployment verifiedVerifiedMay 1, 2026
LIBERTY Endovascular Robotic System at North Carolina, USA
- Deployment verifiedVerifiedMar 26, 2026
LIBERTY Endovascular Robotic System at Atlanta, Georgia, USA
- Deployment verifiedVerifiedMar 2, 2026
LIBERTY Endovascular Robotic System at Tampa, Florida, USA
- Incident recordedSep 8, 2025
Microbot Medical receives FDA 510(k) clearance for Liberty endovascular robotic system
Sources (1)
Common questions
What is Microbot Medical?
What does Microbot Medical make?
Who competes with Microbot Medical?
Who is the CEO of Microbot Medical?
Where is Microbot Medical headquartered?
Where does Microbot Medical operate robots?
Is Microbot Medical a top robotics company?
When was Microbot Medical founded?
Are there any incidents involving Microbot Medical?
Is Microbot Medical safe?
Methodology: Verified · 1 source (1 primary) · last reviewed 2026-08-11
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-08-11
Sources by quality tier
- 1
- primary-company-ir
- Company IR disclosure
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Microbot Medical.Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
In the press
Recent coverage mentioning Microbot Medical from third-party publications. Automatically surfaced; not part of the verified registry record.
Why Microbot Medical thinks it can win the stroke telesurgery race
Microbot Medical says it has what it takes to win the race to treat stroke patients with a future version of its fully disposable, single-use endovascular navigation surgical…
Microbot Medical Wins Surgical Robotics Industry Award for the LIBERTY Endovascular Robotic System
Microbot Medical won the 2026 Innovative Start-Up Award from Surgical Robotics Technology for its FDA-cleared LIBERTY Endovascular Robotic System, now adopted across seven U.S.…
Microbot Medical Announces First Health System in Michigan to Adopt the LIBERTY System
A notable health system became the first in Michigan to adopt the LIBERTY Endovascular Robotic System, expanding Microbot's footprint to six states.
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue
Microbot Medical recorded revenue in Q1 2026 from the Limited Market Release of the LIBERTY system; full market release now underway with hospitals in six states adopting the…
Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures Using LIBERTY System
Emory Healthcare performed the world's first robotic prostate artery embolization and first robotic Y-90 radioembolization mapping for liver cancer using Microbot's LIBERTY system.
Tampa General Hospital adopts LIBERTY endovascular robotic system
Tampa General Hospital became the first health system in Florida to adopt Microbot Medical's LIBERTY endovascular robotic system, marking early post-FDA-clearance momentum.
Microbot Medical closes 2.2M financing
Microbot Medical exercised investment options worth up to 2.2 million in gross proceeds, following FDA 510(k) clearance of the LIBERTY system.
Microbot Medical Receives FDA 510(k) Clearance for Its LIBERTY Endovascular Robotic System
Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, the first single-use remotely operated endovascular surgical robot.
Microbot Medical secures FDA clearance for endovascular surgical robot
Microbot Medical's Liberty endovascular surgical robot earns 510(k) FDA clearance, making it the first FDA-cleared single-use, remotely operated robotic system for peripheral…
Microbot Medical Receives FDA 510(k) Clearance for Its LIBERTY Endovascular Robotic System
Microbot Medical received FDA 510(k) clearance for the LIBERTY system, the first single-use remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical Wins Surgical Robotics Industry Award for the LIBERTY Endovascular Robotic System
Microbot Medical won a surgical robotics industry award for LIBERTY, the only FDA-cleared single-use remotely operated robotic system for peripheral endovascular procedures.
FDA clears Microbot Medical's Liberty endovascular surgical robot
Microbot Medical received FDA 510(k) clearance for its Liberty endovascular surgical robot, the first single-use remotely operated system for peripheral endovascular procedures.
Machine-readable surfaces
- Markdown mirror: /companies/microbot-medical.md
- RSS feed: /companies/microbot-medical/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/02ead9de-6bce-472d-9e76-d9c954d8d603
- Revision history: /companies/microbot-medical/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Brainlab2 models
- EndoQuest Robotics2 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
Video
Microbot Medical specializes in the researching, designing, developing and commercializing of transformational micro-robotics assisted medical technologies.
Microbot Medical Reveals – LIBERTY – the World’s First Fully Disposable Robotic System for Endovascular Procedures
🩺 The future of robotic surgery is here with Microbot Medical’s LIBERTY system! Fully disposable and compact, LIBERTY is designed for neurovascular, cardiovasc
This Stockteller episode provides a strategic overview of Microbot Medical ($MBOT). We dive into their ambitious strategy to develop and commercialize what they
Discover how microbots are transforming medicine! From precise surgeries to cellular repairs, the future of healthcare is here. #Microbots #Robotics #Healthcare
We've all seen dramatic drone shows where hundreds of flying machines are programmed to perform precise maneuvers and dazzling displays. Imagine hundreds of mic
Watch CEO Harel Gadot of Microbot Medical discuss what's next for the company's LIBERTY® Endovascular Robotic System, the first single-use, remotely operated ro
Drive The Future of Intervention™ LIBERTY® is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it
Harel Gadot, CEO, President and Chairman of Microbot Medical Announces LIBERTY® Limited Market Release. Read the latest MBOT News: https://ir.microbotmedical.c
Reality vs attention
Microbot Medical draws attention at the 77th percentile but verifies reality at the 85th percentile among surgical robots. Hype Gap -8.1, 24th widest among surgical robots.
6-month trend
Analysis
Safety profile within acceptable range for category. Funded with institutional backing on record. Limited public visibility and press coverage relative to peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Aug 17, 2026